Key points are not available for this paper at this time.
This study aims to identify laboratory and genetic markers important for COVID-19 severity to improve patient assessment and treatment. COVID-19 patients were divided into two groups based on disease severity. Clinical, laboratory (complete blood count, complete biochemical parameters - lactate dehydrogenase (LDH), serum ferritin), and genetic markers ( OAS1 rs4767027) were analyzed. A total of 61 COVID-19 patients and 48 negative controls were investigated. Group I showed more often lymphopenia – 3.16 (1.39–3.89) vs 5.61(4.21–7.98), p-0.027 and thrombocytopenia – 165 (75–256) vs 212 (198–349), p-0.031, higher LDH (621 ± 218 U/L vs 312 ± 110 U/L), p-0.014. OAS1 rs4767027 genotype and allele frequencies did not differ significantly from worldwide population frequencies. Lymphopenia and thrombocytopenia are likely associated with immune inflammation and COVID-19 severity. While increased OAS1 transcript levels are correlated with reduced risk of infection, they can contribute to NLRP3 inflammasome activation once the infection has been established.
Kadiyska et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: